Agios Pharmaceuticals, Inc. Share Price
NASDAQ: AGIO | Small CapAgios Pharmaceuticals, Inc. Stock Performance
Open $32.15 | Prev. Close $31.93 | Circuit Range N/A |
Day Range $31.57 - $32.60 | Year Range $22.25 - $46.00 | Volume 64,946 |
Average Traded $32.03 |
Agios Pharmaceuticals, Inc. Share Price Today
As of 10 August 2026, Agios Pharmaceuticals, Inc.'s share price is $32.25. The stock opened at $32.15, compared to its previous close of $31.93. During today's trading session, Agios Pharmaceuticals, Inc.'s share price traded between $31.57 and $32.60, with an average price of $32.09. Over the past 52 weeks, the stock has recorded a high of $46.00 and a low of $22.25. In terms of performance, Agios Pharmaceuticals, Inc.'s share price has risen by 6.72% over the last six months and is down 14.41% on a year-on-year basis.
Agios Pharmaceuticals, Inc. Share Price Chart
Agios Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.87B | PE Ratio (TTM) -4.53 | Dividend Yield N/A |
EPS (TTM) $-7.12 | Revenue (TTM) $54.03M | Return On Equity (TTM) -34.60% |
Profit Margin -764.01% | Debt to Equity 0.07 | Quarterly Earnings Growth YoY -110.91% |
Agios Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Agios Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $30.13 | $32.25 | +7.59% |
Jul 2026 | $37.17 | $29.98 | -19.22% |
Jun 2026 | $29.04 | $37.10 | +26.23% |
May 2026 | $28.02 | $29.39 | +5.00% |
Apr 2026 | $33.89 | $28.00 | -17.25% |
Mar 2026 | $29.25 | $33.83 | +11.95% |
Feb 2026 | $27.88 | $30.22 | +10.05% |
Jan 2026 | $27.18 | $27.46 | +0.84% |
Dec 2025 | $28.54 | $27.23 | -6.71% |
Nov 2025 | $42.97 | $29.19 | -32.52% |
Oct 2025 | $40.07 | $43.26 | +7.69% |
Sep 2025 | $37.95 | $40.17 | +6.61% |
AGIO Share Price FAQs
What is Agios Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Agios Pharmaceuticals, Inc. stock?
What is AGIO's market capitalisation today?
What is AGIO's net income for the last quarter?
What is the 5 year returns of AGIO?
What is the high & low stock price of AGIO today?
Can I buy AGIO shares in India?